Profit increased in the first quarter for Danish pharmaceutical company Novo Nordisk compared to the previous year.
First-quarter net profit increased by 28% to 25.41 billion Danish kroner ($3 billion), the company reported.
Earnings per share increased by 29% to 5.68 kroner.
Operating profit increased by 27% in kroner and by 30% at constant exchange rates (CER) to 31.8 billion kroner.
First quarter sales increased by 22% measured in kroner and by 24% at CER to 65.35 billion kroner in the first three months of 2024.
For 2024, the company now expects operating profit growth to be 22% to 30% at CER.
Given the current exchange rates versus the Danish krone, growth reported in DKK is expected to be in line with CER.
Previous guidance was operating profit growth of 21% to 29% at CER.
For 2024, the company now expects sales growth to be 19% to 27% at CER.
Given the current exchange rates versus the krone, sales growth reported in DKK is now expected to be in line with CER.
Prior guidance was sales growth of 18% to 26% at CER.